Cipla Past Earnings Performance
Past criteria checks 2/6
Cipla has been growing earnings at an average annual rate of 17.3%, while the Pharmaceuticals industry saw earnings growing at 15.4% annually. Revenues have been growing at an average rate of 7.6% per year. Cipla's return on equity is 11.2%, and it has net margins of 14%.
Key information
17.31%
Earnings growth rate
17.28%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.49% |
| Revenue growth rate | 7.59% |
| Return on equity | 11.19% |
| Net Margin | 14.00% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Analysis Article • May 16
Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...
Narrative Update • Apr 27
CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook
Analysts now place Cipla's fair value at ₹1,429.83, a small move from ₹1,427.58. This reflects refreshed assumptions around revenue growth, profit margin and future P/E expectations.Narrative Update • Apr 12
CIPLA: New CEO And Biologics Venture Will Support Stronger Outlook
Cipla's analyst fair value estimate has been adjusted slightly from about ₹1,436.58 to ₹1,427.58, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations according to analysts. What's in the News Cipla plans a board meeting on May 13, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for the year, if any (company filing).Narrative Update • Mar 27
CIPLA: New CEO And Biologics Venture Will Support Stronger Long Term Outlook
Analysts have trimmed Cipla's implied fair value price target slightly from ₹1,446.31 to ₹1,436.58, reflecting updated views on its revenue growth, profit margin outlook, and future P/E assumptions. What's in the News A board meeting is scheduled for 19 Mar 2026 to consider appointing P R Ramesh, Lead Independent Director, as Vice Chairman, and to take up the planned exit of Independent Director Robert Stewart after completion of his current term, along with other matters (Key Developments).Narrative Update • Mar 13
CIPLA: Pfizer Alliance And CEO Transition Will Shape Steady Forward Outlook
Analysts have kept their Cipla price target unchanged at ₹1,446.31, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E in their models. What's in the News Cipla has agreed to a 60:40 joint venture with Kemwell Biopharma in India to develop, obtain licenses for, manufacture, commercialise, import and export biologic products, with scope to license or outsource these activities (company announcement).Narrative Update • Feb 27
CIPLA: Pfizer Tie-Up And Leadership Shift Will Shape Balanced Outlook
Analysts have trimmed their price target on Cipla by about ₹10 to reflect slightly softer assumptions around long term revenue growth and profit margins, while keeping the P/E framework broadly unchanged. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, including Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C, while Pfizer continues to manufacture and supply these medicines (Key Developments).Narrative Update • Feb 13
CIPLA: Pfizer Partnership And Upcoming Results Will Guide Balanced Future Expectations
Analysts have trimmed their price target for Cipla slightly to ₹1,456 from about ₹1,459, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E that are broadly in line with prior views. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, covering Corex Dx and Corex LS cough syrups, Dolonex (NSAID), Neksium (PPI) and Dalacin C (oral antibiotic).Narrative Update • Jan 30
CIPLA: Pfizer Alliance And Upcoming Results Will Shape Measured Future Upside Potential
Analysts have revised their fair value estimate for Cipla to ₹1,458.53, down from ₹1,657.58, citing updated assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Cipla has scheduled a board meeting on Jan 23, 2026, at 11:00 Indian Standard Time to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Analysis Article • Jan 28
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...Analysis Article • Jan 17
The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet
With a price-to-earnings (or "P/E") ratio of 20.7x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...Narrative Update • Jan 16
CIPLA: Pfizer Partnership And Leadership Transition Will Support Future Upside Potential
Analysts have slightly reduced their fair value estimate for Cipla to ₹1,658 from ₹1,677, citing updated assumptions that combine modestly higher revenue growth expectations with some pressure on profit margins and a marginally adjusted future P/E multiple. What's in the News A board meeting is scheduled on January 23, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Analysis Article • Dec 29
We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Nov 20
Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • Nov 02
Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...Analysis Article • Sep 24
Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 22.9x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...Analysis Article • Sep 06
Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Narrative Update • Sep 04
Emerging Markets And Chronic Therapies Will Open New Horizons
With consensus forecasts for both revenue growth (8.4% p.a.) and net profit margin (15.92%) remaining steady, Cipla's Analyst Price Target was left unchanged at ₹1677. What's in the News Cipla is significantly expanding its US manufacturing capacity with an 83,000-square-foot addition at its Fall River, Massachusetts facility, focusing on complex respiratory products, and will utilize advanced technology to enhance production and efficiency.Analysis Article • Jul 13
Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Jun 03
Here's Why Cipla (NSE:CIPLA) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Narrative • Nov 10
Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions
Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Cipla makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 277,117 | 38,792 | 53,663 | 0 |
| 31 Dec 25 | 279,672 | 45,464 | 64,591 | 0 |
| 30 Sep 25 | 279,658 | 54,411 | 63,317 | 0 |
| 30 Jun 25 | 274,796 | 53,925 | 62,248 | 0 |
| 31 Mar 25 | 272,674 | 52,725 | 61,067 | 0 |
| 31 Dec 24 | 267,201 | 49,897 | 58,640 | 0 |
| 30 Sep 24 | 262,642 | 44,751 | 57,345 | 0 |
| 30 Jun 24 | 258,922 | 43,035 | 56,178 | 0 |
| 31 Mar 24 | 255,367 | 41,216 | 54,901 | 0 |
| 31 Dec 23 | 251,163 | 37,082 | 53,757 | 0 |
| 30 Sep 23 | 243,407 | 34,532 | 52,563 | 0 |
| 30 Jun 23 | 235,108 | 31,112 | 51,260 | 0 |
| 31 Mar 23 | 225,593 | 28,019 | 50,151 | 0 |
| 31 Dec 22 | 222,187 | 26,383 | 48,947 | 0 |
| 30 Sep 22 | 218,874 | 25,660 | 48,184 | 0 |
| 30 Jun 22 | 216,105 | 24,884 | 35,984 | 0 |
| 31 Mar 22 | 217,078 | 25,168 | 46,669 | 0 |
| 31 Dec 21 | 210,718 | 25,681 | 43,285 | 0 |
| 30 Sep 21 | 207,616 | 25,876 | 43,004 | 0 |
| 30 Jun 21 | 202,801 | 25,417 | 42,435 | 0 |
| 31 Mar 21 | 191,205 | 24,049 | 41,281 | 0 |
| 31 Dec 20 | 188,779 | 22,374 | 40,432 | 0 |
| 30 Sep 20 | 180,802 | 18,403 | 39,444 | 0 |
| 30 Jun 20 | 174,377 | 16,462 | 38,851 | 0 |
| 31 Mar 20 | 170,805 | 15,465 | 38,694 | 0 |
| 31 Dec 19 | 171,206 | 16,678 | 38,608 | 0 |
| 30 Sep 19 | 167,572 | 16,489 | 38,331 | 0 |
| 30 Jun 19 | 163,733 | 15,546 | 37,837 | 0 |
| 31 Mar 19 | 163,232 | 15,277 | 37,415 | 0 |
| 31 Dec 18 | 155,224 | 13,391 | 35,683 | 0 |
| 30 Sep 18 | 154,287 | 14,074 | 35,078 | 0 |
| 30 Jun 18 | 154,992 | 14,530 | 34,564 | 0 |
| 31 Mar 18 | 151,053 | 14,105 | 34,151 | 0 |
| 31 Dec 17 | 147,618 | 11,701 | 32,973 | 0 |
| 30 Sep 17 | 144,951 | 11,444 | 32,730 | 0 |
| 30 Jun 17 | 141,637 | 10,762 | 32,875 | 0 |
| 31 Mar 17 | 143,340 | 10,064 | 33,011 | 0 |
| 31 Dec 16 | 142,509 | 11,213 | 31,554 | 0 |
| 30 Sep 16 | 137,547 | 10,071 | 31,012 | 0 |
| 30 Jun 16 | 134,335 | 12,219 | 30,089 | 0 |
| 31 Mar 16 | 135,480 | 13,600 | 29,258 | 0 |
| 31 Dec 15 | 135,044 | 16,847 | 39,028 | 1,120 |
| 30 Sep 15 | 131,633 | 16,694 | 38,220 | 1,120 |
| 30 Jun 15 | 124,782 | 15,368 | 37,096 | 1,120 |
Quality Earnings: CIPLA has high quality earnings.
Growing Profit Margin: CIPLA's current net profit margins (14%) are lower than last year (19.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CIPLA's earnings have grown by 17.3% per year over the past 5 years.
Accelerating Growth: CIPLA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CIPLA had negative earnings growth (-26.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (13.6%).
Return on Equity
High ROE: CIPLA's Return on Equity (11.2%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/25 23:40 |
| End of Day Share Price | 2026/05/25 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cipla Limited is covered by 56 analysts. 35 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |